This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's What Key Metrics Tell Us About Privia Health (PRVA) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health (PRVA) Lags Q2 Earnings Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -40% and 2.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 33.33% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 62.50% and 1.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Privia Health (PRVA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DH or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DH vs. PRVA: Which Stock Is the Better Value Option?
Here's What Key Metrics Tell Us About Privia Health (PRVA) Q1 Earnings
by Zacks Equity Research
The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Privia Health (PRVA) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 4.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health (PRVA) Misses Q4 Earnings Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OMCL vs. PRVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OMCL vs. PRVA: Which Stock Is the Better Value Option?
Compared to Estimates, Privia Health (PRVA) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Privia Health (PRVA) Q3 Earnings Miss Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -16.67% and 1.59%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
GEHC or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
GEHC or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
GEHC or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
Privia Health (PRVA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 20% and 5.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
GEHC vs. PRVA: Which Stock Is the Better Value Option?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
Privia Health (PRVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 100% and 2.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Privia Health (PRVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Signify (SGFY): Can Its 5.8% Jump Turn into More Strength?
by Zacks Equity Research
Signify (SGFY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Options Traders Betting on a Big Move in Privia Health Group (PRVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Privia Health Group (PRVA) stock based on the movements in the options market lately.
Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50% and 11.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -400% and 7.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 8.11% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?